LAVA Therapeutics NV
LVTX
Market Cap$34.46M
Close$
$-2.51
290.5% downside
Current Fair Value
290.5% downsideOvervalued by 290.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.46 Million |
|---|---|
| Enterprise Value | $5.16 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.94 |
| Beta | 0.45 |
| Outstanding Shares | 26,892,575 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.26 |
|---|---|
| PEG | -0.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.99 |
| Enterprise Value to EBIT | -0.22 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.01 |
| Debt to Equity | 0.4 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About LAVA Therapeutics NV
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The...